Tuesday, March 31, 2020
ImaginAb Inc., a leading clinical stage immuno-oncology imaging company, announced it has signed a multi-year non-exclusive license agreement with AstraZeneca.
Under the terms of the agreement, ImaginAb's CD8 ImmunoPET technology will be used in AstraZeneca's clinical trials in North America and Europe to facilitate clinical development of AstraZeneca's novel immunotherapies and to advance the clinical utility of ImaginAb's CD8 ImmunoPET.
The deal is an opportunity for ImaginAb to support AstraZeneca's project teams on imaging CD8 cells in patients and both teams will be committed to analysing and interpreting the data for their respective research and development activities.
ImaginAb will receive license fees and other contingent payments.
This agreement follows the recently signed pre-competitive alliance between AstraZeneca, ImaginAb and other global pharmaceutical companies, announced on October 14, 2019.
